PFAS’s Forever Problem: Ohio Lawsuit Against Chemical Companies Fizzles Out
Big chemical companies won a lawsuit preventing 11.8 million Ohio residents from suing them for PFAS chemicals in their blood.
German Conglomerate Bayer Faces Investor Scrutiny Amid Unexpected Legal, Trial Setbacks
Bayer AG (OTC: BAYRY) (OTC: BAYZF) reportedly held an investor call to address concerns after intense scrutiny from investors following a series of unforeseen setbacks, prompting questions about transparency surrounding its
Analyst Assess Implications of Bristol Myers’ Investigational Blood Thinner Post Bayer Trial Setback Amid Shaken Investor Confidence
Monday, Bayer AG (OTC: BAYRY) (OTC: BAYZF)
Bayer’s Blood Thinner Study Stopped Early Due To Lack Of Efficacy: Details
Bayer AG (OTC: BAYRY) (OTC: BAYZF)
Bayer’s Legal Victory Against Merck: Delaware Court Rules In Company’s Favor Regarding Talc Lawsuits
The Delaware Supreme Court reportedly ruled in favor of Bayer AG (OTC: BAYRY) (OTC: BAYZF), stating that the company is not accountable for lawsuits associated with talc-based foot powder products obtained from Merck
Bayer CEO Resists Full Tri-Split, German Conglomerate Cuts Management Jobs In The Face Of Q3 Loss
Bayer AG (OTC: BAYRY) (OTC: BAYZF) CEO Bill Anderson announced
Legal Woes Mount for Bayer As Roundup Weed Killer-Related Cancer Cases Continue, Faces Third Trial Loss
Bayer AG (OTC: BAYRY) (OTC:
AI To Revolutionize Clinical Trials And Diagnostics
With the help of technology, the pharmaceutical industry is gaining new insights that are fueling the development of next generation of drugs while also speeding up clinical trials and improving diagnostics.
From Years to Months: How AI is Shaping the Landscape of Clinical Trials
Pharmaceutical companies are harnessing artificial intelligence (AI) to speed up the traditionally arduous process of clinical trials, potentially saving both time and significant sums of money. These human studies, crucial to drug development, can take years and accrue costs in the billions.
FDA Panel Says Popular OTC Cold, Allergy Medicine Might Be Useless – Stocks To Watch
According to FDA panel experts who reviewed the latest research on the long-questioned phenylephrine, a drug ingredient used in several leading decongestants used by millions of Americans looking for relief from